It’s not looking so great for the would-be “female Viagra,” as Bloomberg News reports the FDA has rejected Sprout Pharmaceuticals’ flibanserin pill. (Guess there’s no need for a sexy brand name until you’ve bagged regulatory approval.) The agency just isn’t convinced the “modest affect” of the drug outweighs potential side effects, which include fatigue and nausea.
Sprout is appealing the decision, though that’s generally considered a long shot, and the company still insists on the drug’s merits. According to Bloomberg News, they say that “in clinical trials, Sprout’s pill almost doubled the increase women saw in satisfying sexual experiences over a month’s time compared with patients who took a placebo.”